Ocular Therapeutix (OCUL)
(Delayed Data from NSDQ)
$12.50 USD
+0.50 (4.17%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $12.48 -0.02 (-0.16%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OCUL 12.50 +0.50(4.17%)
Will OCUL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OCUL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OCUL
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
OCUL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates
Other News for OCUL
Scotiabank Lowers Price Target for Ocular Therapeutix (OCUL) | OCUL Stock News
Ocular Therapeutix price target lowered to $20 from $22 at Scotiabank
Ocular Therapeutix price target lowered by $2 at Scotiabank, here's why
Ocular Therapeutix Inc (OCUL) Q2 2025 Earnings Call Highlights: Strategic Advances and ...
Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript